Kijun Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kijun Song has a total of 270 co-authors. Here are the top co-authors by number of shared publications:
- Hyuk-Soo Seo
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
24 shared publications - Sirano Dhe-Paganon
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
20 shared publications - Alexander Beck
Center for Neuropathology, Ludwig-Maximilians-University, 81377 Munich, Germany
15 shared publications - Amy Goodale
Broad Institute, Cambridge, MA, USA
15 shared publications - Amy Saur Conway
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
15 shared publications - Andrew Groves
Harvard Medical School Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Boston, Massachusetts
15 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Mechanistic and antigenic boundaries of Henipavirus and Parahenipavirus glycoproteins
Henipaviruses, in the Paramyxoviridae family, includes the highly virulent Nipah virus that causes reoccurring outbreaks of deadly disease. Recent discoveries of Henipavirus-like species, including the zoonotic Langya virus, have revealed much higher antigenic diversity than currently characterized and prompted the reorganization of these viruses into the Henipavirus and Parahenipavirus genera. Here, to explore the limits of structural and antigenic variation in both genera, collectively referred to as HNVs, we construct an expanded, diverse panel of HNV fusion and attachment glycoproteins from non-redundant HNV strains that better reflect global HNV diversity. We express and purify the fusion protein ectodomains and the attachment protein head domains and study their biochemical and biophysical properties. We perform immunization experiments in mice, eliciting antibodies reactive to multiple HNV fusion proteins. Cryo-electron microscopy structures elucidate molecular determinants of differential pre-fusion state stability and higher order contacts. A crystal structure of the Gamak virus attachment head domain reveals an additional domain appended to the conserved 6-bladed, β-propeller fold. Taken together, these studies expand the known structural and antigenic limits of the HNVs, reveal cross-reactive epitopes within both genera and provide foundational data for the development of broadly reactive countermeasures.
- 19 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMechanistic and antigenic boundaries of Henipavirus and Parahenipavirus glycoproteins
Henipaviruses, in the Paramyxoviridae family, includes the highly virulent Nipah virus that causes reoccurring outbreaks of deadly disease. Recent discoveries of Henipavirus-like species, including the zoonotic Langya virus, have revealed much higher antigenic diversity than currently characterized and prompted the reorganization of these viruses into the Henipavirus and Parahenipavirus genera. Here, to explore the limits of structural and antigenic variation in both genera, collectively referred to as HNVs, we construct an expanded, diverse panel of HNV fusion and attachment glycoproteins from non-redundant HNV strains that better reflect global HNV diversity. We express and purify the fusion protein ectodomains and the attachment protein head domains and study their biochemical and biophysical properties. We perform immunization experiments in mice, eliciting antibodies reactive to multiple HNV fusion proteins. Cryo-electron microscopy structures elucidate molecular determinants of differential pre-fusion state stability and higher order contacts. A crystal structure of the Gamak virus attachment head domain reveals an additional domain appended to the conserved 6-bladed, β-propeller fold. Taken together, these studies expand the known structural and antigenic limits of the HNVs, reveal cross-reactive epitopes within both genera and provide foundational data for the development of broadly reactive countermeasures.
- Open Access
- 14 May 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (6) , 1393-1416
Targeting transcription factors through an IMiD independent zinc finger domain
Immunomodulatory imide drugs (IMiDs) degrade specific C2H2 zinc finger degrons in transcription factors, making them effective against certain cancers. SALL4, a cancer driver, contains seven C2H2 zinc fingers in three clusters, including an IMiD degron in zinc finger cluster one (ZFC1). Surprisingly, IMiDs do not inhibit the growth of SALL4-expressing cancer cells. To overcome this limit, we focused on a non-IMiD domain, SALL4 zinc finger cluster four (ZFC4). By combining ZFC4-DNA crystal structure and an in silico docking algorithm, in conjunction with cell viability assays, we screened several chemical libraries against a potentially druggable binding pocket, leading to the discovery of SH6, a compound that selectively targets SALL4-expressing cancer cells. Mechanistic studies revealed that SH6 degrades SALL4 protein through the CUL4A/CRBN pathway, while deletion of ZFC4 abolished this activity. Moreover, SH6 treatment led to a significant 87% tumor growth inhibition of SALL4+ patient-derived xenografts and demonstrated good bioavailability in pharmacokinetic studies. In summary, these studies represent a new approach for IMiD independent drug discovery targeting C2H2 transcription factors such as SALL4 in cancer.
- 14 May 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (6) , 1393-1416
Open AccessTargeting transcription factors through an IMiD independent zinc finger domain
Immunomodulatory imide drugs (IMiDs) degrade specific C2H2 zinc finger degrons in transcription factors, making them effective against certain cancers. SALL4, a cancer driver, contains seven C2H2 zinc fingers in three clusters, including an IMiD degron in zinc finger cluster one (ZFC1). Surprisingly, IMiDs do not inhibit the growth of SALL4-expressing cancer cells. To overcome this limit, we focused on a non-IMiD domain, SALL4 zinc finger cluster four (ZFC4). By combining ZFC4-DNA crystal structure and an in silico docking algorithm, in conjunction with cell viability assays, we screened several chemical libraries against a potentially druggable binding pocket, leading to the discovery of SH6, a compound that selectively targets SALL4-expressing cancer cells. Mechanistic studies revealed that SH6 degrades SALL4 protein through the CUL4A/CRBN pathway, while deletion of ZFC4 abolished this activity. Moreover, SH6 treatment led to a significant 87% tumor growth inhibition of SALL4+ patient-derived xenografts and demonstrated good bioavailability in pharmacokinetic studies. In summary, these studies represent a new approach for IMiD independent drug discovery targeting C2H2 transcription factors such as SALL4 in cancer.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Table from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas.Significance:Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma.See related commentary by Beytagh and Weiss, p. 2730.See related article by Mo et al., p. 2906.This article is highlighted in the In This Issue feature, p. 2711
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Supplementary Figure from BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma